-
Something wrong with this record ?
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy
CT. Huang, X. Guo, C. Bařinka, SE. Lupold, MG. Pomper, K. Gabrielson, V. Raman, D. Artemov, S. Hapuarachchige
Language English Country United States
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
Grant support
P41 EB024495
NIBIB NIH HHS - United States
R01 CA209884
NCI NIH HHS - United States
- MeSH
- Androstenes pharmacology MeSH
- Androgen Antagonists pharmacology MeSH
- Antigens, Surface metabolism MeSH
- Benzamides pharmacology MeSH
- PC-3 Cells MeSH
- Centrosome metabolism MeSH
- Phenylthiohydantoin pharmacology MeSH
- Glutamate Carboxypeptidase II metabolism MeSH
- Immunoconjugates pharmacology MeSH
- Humans MeSH
- Tubulin Modulators pharmacology MeSH
- Antibodies, Monoclonal pharmacology MeSH
- Mice, Nude MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms, Castration-Resistant drug therapy metabolism MeSH
- Nitriles pharmacology MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
Prostate cancer (PC) is a potentially high-risk disease and the most common cancer in American men. It is a leading cause of cancer-related deaths in men in the US, second only to lung and bronchus cancer. Advanced and metastatic PC is initially treated with androgen deprivation therapy (ADT), but nearly all cases eventually progress to castrate-resistant prostate cancer (CRPC). CRPC is incurable in the metastatic stage but can be slowed by some conventional chemotherapeutics and second-generation ADT, such as enzalutamide and abiraterone. Therefore, novel therapeutic strategies are urgently needed. Prostate-specific membrane antigen (PSMA) is overexpressed in almost all aggressive PCs. PSMA is widely used as a target for PC imaging and drug delivery. Anti-PSMA monoclonal antibodies (mAbs) have been developed as bioligands for diagnostic imaging and targeted PC therapy. However, these mAbs are successfully used in PC imaging and only a few have gone beyond phase-I for targeted therapy. The 5D3 mAb is a novel, high-affinity, and fast-internalizing anti-PSMA antibody. Importantly, 5D3 mAb demonstrates a unique pattern of cellular localization to the centrosome after internalization in PSMA(+) PC3-PIP cells. These characteristics make 5D3 mAb an ideal bioligand to deliver tubulin inhibitors, such as mertansine, to the cell centrosome, leading to mitotic arrest and elimination of dividing PC cells. We have successfully developed a 5D3 mAb- and mertansine (DM1)-based antibody-drug conjugate (ADC) and evaluated it in vitro for binding affinity, internalization, and cytotoxicity. The in vivo therapeutic efficacy of 5D3-DM1 ADC was evaluated in PSMA(+) PC3-PIP and PSMA(-) PC3-Flu mouse models of human PC. This therapeutic study has revealed that this new anti-PSMA ADC can successfully control the growth of PSMA(+) tumors without inducing systemic toxicity.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026563
- 003
- CZ-PrNML
- 005
- 20211026132812.0
- 007
- ta
- 008
- 211013s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.0c00457 $2 doi
- 035 __
- $a (PubMed)32803984
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Huang, Colin T $u The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, United States
- 245 10
- $a Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy / $c CT. Huang, X. Guo, C. Bařinka, SE. Lupold, MG. Pomper, K. Gabrielson, V. Raman, D. Artemov, S. Hapuarachchige
- 520 9_
- $a Prostate cancer (PC) is a potentially high-risk disease and the most common cancer in American men. It is a leading cause of cancer-related deaths in men in the US, second only to lung and bronchus cancer. Advanced and metastatic PC is initially treated with androgen deprivation therapy (ADT), but nearly all cases eventually progress to castrate-resistant prostate cancer (CRPC). CRPC is incurable in the metastatic stage but can be slowed by some conventional chemotherapeutics and second-generation ADT, such as enzalutamide and abiraterone. Therefore, novel therapeutic strategies are urgently needed. Prostate-specific membrane antigen (PSMA) is overexpressed in almost all aggressive PCs. PSMA is widely used as a target for PC imaging and drug delivery. Anti-PSMA monoclonal antibodies (mAbs) have been developed as bioligands for diagnostic imaging and targeted PC therapy. However, these mAbs are successfully used in PC imaging and only a few have gone beyond phase-I for targeted therapy. The 5D3 mAb is a novel, high-affinity, and fast-internalizing anti-PSMA antibody. Importantly, 5D3 mAb demonstrates a unique pattern of cellular localization to the centrosome after internalization in PSMA(+) PC3-PIP cells. These characteristics make 5D3 mAb an ideal bioligand to deliver tubulin inhibitors, such as mertansine, to the cell centrosome, leading to mitotic arrest and elimination of dividing PC cells. We have successfully developed a 5D3 mAb- and mertansine (DM1)-based antibody-drug conjugate (ADC) and evaluated it in vitro for binding affinity, internalization, and cytotoxicity. The in vivo therapeutic efficacy of 5D3-DM1 ADC was evaluated in PSMA(+) PC3-PIP and PSMA(-) PC3-Flu mouse models of human PC. This therapeutic study has revealed that this new anti-PSMA ADC can successfully control the growth of PSMA(+) tumors without inducing systemic toxicity.
- 650 _2
- $a antagonisté androgenů $x farmakologie $7 D000726
- 650 _2
- $a androsteny $x farmakologie $7 D000736
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a monoklonální protilátky $x farmakologie $7 D000911
- 650 _2
- $a antigeny povrchové $x metabolismus $7 D000954
- 650 _2
- $a benzamidy $x farmakologie $7 D001549
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a centrozom $x metabolismus $7 D018385
- 650 _2
- $a glutamátkarboxypeptidasa II $x metabolismus $7 D043425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunokonjugáty $x farmakologie $7 D018796
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši nahé $7 D008819
- 650 _2
- $a nitrily $x farmakologie $7 D009570
- 650 _2
- $a buňky PC-3 $7 D000078722
- 650 _2
- $a fenylthiohydantoin $x farmakologie $7 D010669
- 650 _2
- $a nádory prostaty rezistentní na kastraci $x farmakoterapie $x metabolismus $7 D064129
- 650 _2
- $a modulátory tubulinu $x farmakologie $7 D050257
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
- 700 1_
- $a Guo, Xin $u Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, Maryland 21205, United States
- 700 1_
- $a Bařinka, Cyril $u Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic
- 700 1_
- $a Lupold, Shawn E $u The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins School of Medicine, 600 N. Wolfe Street, Baltimore, Maryland 21287, United States
- 700 1_
- $a Pomper, Martin G $u The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, United States $u The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins School of Medicine, 600 N. Wolfe Street, Baltimore, Maryland 21287, United States $u Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 401 N. Broadway, Baltimore, Maryland 21287, United States
- 700 1_
- $a Gabrielson, Kathleen $u Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, Maryland 21205, United States
- 700 1_
- $a Raman, Venu $u The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, United States $u Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 401 N. Broadway, Baltimore, Maryland 21287, United States
- 700 1_
- $a Artemov, Dmitri $u The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, United States $u Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 401 N. Broadway, Baltimore, Maryland 21287, United States
- 700 1_
- $a Hapuarachchige, Sudath $u The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, United States
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 17, č. 9 (2020), s. 3392-3402
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32803984 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132818 $b ABA008
- 999 __
- $a ok $b bmc $g 1715328 $s 1147070
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 17 $c 9 $d 3392-3402 $e 20200817 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- GRA __
- $a P41 EB024495 $p NIBIB NIH HHS $2 United States
- GRA __
- $a R01 CA209884 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20211013